Pierson Patricia M, Peteri-Brunbäck Brigitta, Pisani Didier F, Abbracchio Maria Pia, Mienville Jean-Marc, Rosso Lia
CNRS UMR 6548, Laboratoire de Physiologie Cellulaire et Moléculaire, Université de Nice-Sophia Antipolis, Nice, France.
Biol Cell. 2007 Aug;99(8):445-54. doi: 10.1042/BC20070028.
Recent work suggests that part of the control of vasopressin output is mediated by taurine released from pituicytes, the astroglial cells of the neurohypophysis. Taurine release, in turn, is stimulated by hypotonic conditions and by vasopressin itself. As adenosine is generated from ATP co-released with vasopressin, it appeared important to study its effects on taurine efflux from pituicytes.
We measured radioactive efflux from cultured pituicytes and whole neurohypophyses pre-loaded with [(3)H]taurine. Cultured pituicytes were also used to study adenosine-receptor mRNA expression. Taurine efflux elicited by hypotonic shocks is approximately 30-50% smaller in the presence of 10 microM adenosine or 1 microM NECA (5'-N-ethylcarboxamidoadenosine). Both compounds also inhibited basal efflux in a manner that was not immediately reversible. Agonists of the adenosine A1-, A2a- or A3-receptor subtypes have no relevant effect on basal taurine release, and the A1-receptor antagonist DPCPX (8-cyclopentyl-1,3-dipropylxanthine) has no effect on the inhibition of release by NECA. In turn, the A2b-receptor antagonists MRS 1706 {N-(4-acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetamide} or alloxazine partially reverse the inhibition of basal or hypotonicity-evoked efflux by NECA. Both A1- and A2b-receptor mRNAs are expressed in pituicytes, which is consistent with an A1-receptor-mediated effect on cell morphology and an A2b-receptor-mediated effect on taurine release. Forskolin and dibutyryl cAMP mimic the inhibitory effects of purinergics on basal taurine efflux, and the adenylate cyclase inhibitor DDA (2',5'-dideoxyadenosine) partially reverses the inhibition of the hypotonic response by NECA.Conclusions. Our results suggest that purinergic inhibition of taurine efflux from pituicytes operates through A2b receptors coupled to intracellular cAMP increase. They point to a possible modulation of neurohypophysial hormone output by endogenous adenosine released in either physiological or pathological situations.
最近的研究表明,血管加压素分泌的部分调控是由垂体细胞(神经垂体的星形胶质细胞)释放的牛磺酸介导的。反过来,低渗条件和血管加压素本身会刺激牛磺酸的释放。由于腺苷是与血管加压素共同释放的三磷酸腺苷(ATP)生成的,因此研究其对垂体细胞牛磺酸外流的影响显得很重要。
我们测量了预先加载[³H]牛磺酸的培养垂体细胞和整个神经垂体的放射性外流。培养的垂体细胞也用于研究腺苷受体mRNA的表达。在存在10微摩尔腺苷或1微摩尔NECA(5'-N-乙基羧酰胺腺苷)的情况下,低渗冲击引起的牛磺酸外流比正常情况减少约30 - 50%。这两种化合物还以不可逆的方式抑制基础外流。腺苷A1、A2a或A3受体亚型的激动剂对基础牛磺酸释放没有相关影响,A1受体拮抗剂DPCPX(8-环戊基-1,3-二丙基黄嘌呤)对NECA抑制释放没有影响。相反,A2b受体拮抗剂MRS 1706(N-(4-乙酰苯基)-2-[4-(2,3,6,7-四氢-2,6-二氧代-1,3-二丙基-1H-嘌呤-8-基)苯氧基]乙酰胺)或咯嗪部分逆转了NECA对基础或低渗诱发外流的抑制作用。A1和A2b受体mRNA均在垂体细胞中表达,这与A1受体介导对细胞形态的影响以及A2b受体介导对牛磺酸释放的影响一致。福斯高林和二丁酰环磷腺苷模仿嘌呤能药物对基础牛磺酸外流的抑制作用,腺苷酸环化酶抑制剂DDA(2',5'-二脱氧腺苷)部分逆转了NECA对低渗反应的抑制作用。
结论。我们的结果表明,嘌呤能对垂体细胞牛磺酸外流的抑制作用是通过与细胞内cAMP增加偶联的A2b受体起作用的。它们指出在生理或病理情况下释放的内源性腺苷可能对神经垂体激素分泌有调节作用。